Table 1 Multivariate Cox regression analysis of tumor-infiltrating lymphocytes and immune markers for relapse-free survival and overall survival in triple-negative breast cancer

LPBC

0.24

0.06–1.00

5.10E-02

0.32

0.10–1.03

5.60E-02

 Age

1.09

0.66–1.80

7.28E-01

1.13

0.68–1.87

6.27E-01

 Histologic grade

1.66

0.78–3.53

1.91E-01

1.85

0.87–3.94

1.09E-01

 Nodal status

3.44

1.72–6.88

5.00E-04

3.19

1.59–6.39

1.00E-03

 Tumor size

1.21

0.74–1.99

4.48E-01

1.27

0.77–2.09

3.48E-01

 Tumor stage

1.34

0.76–2.35

3.12E-01

1.38

0.78–2.43

2.69E-01

TILs^a

0.93

0.89–0.96

1.00E-04

0.93

0.90–0.95

1.00E-04

 Age

0.97

0.58–1.61

8.97E-01

1.02

0.61–1.71

9.32E-01

 Histologic grade

1.34

0.63–2.87

4.48E-01

1.76

0.83–3.75

1.40E-01

 Nodal status

2.91

1.43–5.90

3.10E-03

2.59

1.27–5.28

8.70E-03

 Tumor size

1.11

0.68–1.83

6.70E-01

1.15

0.70–1.90

5.73E-01

 Tumor stage

1.46

0.82–2.62

2.00E-01

1.45

0.80–2.63

2.19E-01

CD8

0.58

0.34–0.97

3.72E-02

0.58

0.34–0.97

3.88E-02

 Age

1.12

0.68–1.85

6.66E-01

1.16

0.70–1.93

5.58E-01

 Histologic grade

1.71

0.80–3.65

1.67E-01

1.91

0.90–4.08

9.34E-02

 Nodal status

3.46

1.73–6.90

4.00E-04

3.23

1.62–6.45

9.00E-04

 Tumor size

1.20

0.73–1.97

4.80E-01

1.26

0.76–2.07

3.70E-01

 Tumor stage

1.35

0.76–2.37

3.01E-01

1.35

0.76–2.40

2.99E-01

FOXP3

0.52

0.31–0.89

1.71E-02

0.55

0.32–0.94

2.90E-02

 Age

1.10

0.67–1.83

6.98E-01

1.16

0.70–1.92

5.70E-01

 Histologic grade

1.81

0.84–3.87

1.28E-01

2.01

0.94–4.30

7.27E-02

 Nodal status

3.54

1.79–7.00

3.00E-04

3.30

1.67–6.53

6.00E-04

 Tumor size

1.23

0.75–2.03

4.05 E-01

1.30

0.79–2.13

3.06E-01

 Tumor stage

1.37

0.79–2.41

2.65E-01

1.38

0.78–2.42

2.66E-01